EVT:XETRA-Evotec SE (EUR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | XETRA

Last Closing Price

EUR 26.88

Change

0.00 (0.00)%

Market Cap

EUR 4.76B

Volume

0.53M

Avg Analyst Target

EUR 40.55 (+50.84%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


EVT Stock Forecast & Price:
Based on the Evotec SE stock forecasts from 6 analysts, the average analyst target price for Evotec SE is EUR 40.55 over the next 12 months. Evotec SE’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Evotec SE is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Evotec SE’s stock price was EUR 26.88. Evotec SE’s stock price has changed by -3.03% over the past week, +9.36% over the past month and -35.38% over the last year.

About Evotec SE (EVT:XETRA)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZOE:XETRA Zoetis Inc

N/A

EUR80.93B 39.25 25.90
MRK:XETRA Merck & Company Inc

N/A

EUR79.83B 24.09 14.41
DMP:XETRA Dermapharm Holding SE

N/A

EUR2.95B 13.87 9.01
PSG:XETRA PharmaSGP Holding SE

N/A

EUR0.30B 25.10 12.86
93M:XETRA MPH Health Care AG

N/A

EUR0.11B 10.19 9.69
HAEK:XETRA Haemato AG

N/A

EUR0.10B 14.37 6.20
APPH:XETRA Apontis Pharma AG

N/A

EUR0.09B N/A 27.58
4BSB:XETRA 4basebio AG

N/A

EUR0.09B 0.17 2.64
PA8:XETRA Paion AG

N/A

EUR0.08B 60.07 -4.33
93M1:XETRA MPH Health Care AG

N/A

EUR0.07B 10.19 -7.99

ETFs Containing EVT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -36.75% 36% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.75% 36% F 5% F
Trailing 12 Months  
Capital Gain -35.38% 50% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.38% 50% F 8% F
Trailing 5 Years  
Capital Gain 86.54% 75% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.54% 75% C 84% B
Average Annual (5 Year Horizon)  
Capital Gain 24.25% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.25% 90% A- 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 32.03% 20% F 22% F
Risk Adjusted Return 75.70% 70% C- 82% B-
Market Capitalization 4.76B 83% B 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 44.07 22% F 17% F
Price/Book Ratio 3.73 58% F 26% F
Price / Cash Flow Ratio 38.91 10% F 6% F
EV/EBITDA 34.82 8% F 4% F
Management Effectiveness  
Return on Equity 0.15% 50% F 23% F
Return on Invested Capital 1.39% 55% F 27% F
Return on Assets 0.88% 42% F 32% F
Debt to Equity Ratio 23.69% 100% A+ 70% C-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.06 45% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.